NCT07648823

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

RecruitingEARLY_PHASE1INTERVENTIONAL

Trial Details

Start: 2026-06-20Est. Completion: 2027-06-20

Enrollment target: 5 participants

Locations

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing Municipality, China

Contact

Li'ao Wang, M.D.wangliao17@163.com +86 15001171671

Deling Li, M.D.lideling@bjtth.org

Other microbiome trials you might be interested in

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPhase 1Recruiting

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed CancerRecurrent TumorGlioblastoma MultiformeRecurring GlioblastomaBrain and Central Nervous System TumorsGliomaGlioblastomasGrade IV AstrocytomaGBMRecurrent Glioma (Glioblastoma Multiforme)High Grade GliomaGlioma, MalignantBrain Cancer

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…

Bethesda, United StatesEst. completion Dec 31, 2030

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.